Gene · 5817
Papers4,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 4,420
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PRDM15 inhibits responses of Tissue-Resident memory T cells by activating PVR/TIGIT axis to mediate gastric cancer immunosuppression. | J Adv Res | 2026 | 41213401 | PubTator, text mining | PubMed |
| CD155 density on target cells drives divergent natural killer cell responses owing to DNAM-1 loss. | J Immunol | 2026 | 41186276 | PubTator, text mining | PubMed |
| Novel Multi-Biomarker Nomogram Combining CD155/CD226/TIGIT/CD96 Immune Checkpoint Axis for Postoperative Survival Prediction in Breast Cancer. | Clin Breast Cancer | 2026 | 41073220 | PubTator, text mining | PubMed |
| Computational screening for natural compounds as potential immune checkpoint inhibitors against TIGIT, a new avenue in cancer immunotherapy. | Mol Divers | 2026 | 40163147 | PubTator, text mining | PubMed |
| Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi. | Blood Glob Hematol | 2025 | 42306579 | PubTator, text mining | PubMed |
| Mechanisms and Therapeutic Strategies to Overcome Immune Checkpoint Inhibitor Resistance in Melanoma, Head and Neck, and Triple-Negative Breast Cancers. | J Cell Immunol | 2025 | 41799379 | PubTator, text mining | PubMed |
| Exploratory Urinary Proteomic Profiling in Pregnancies with Fetal Aneuploidies: Molecular Insights into Maternal-Fetal Metabolic Communication. | Curr Issues Mol Biol | 2025 | 41614738 | PubTator, text mining | PubMed |
| Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition. | Front Immunol | 2025 | 41613119 | PubTator, text mining | PubMed |
| Natural killer cell exhaustion in ovarian cancer: from molecular suppression to therapeutic revival. | Front Immunol | 2025 | 41567203 | PubTator, text mining | PubMed |
| An interpretative review of North American expert consensus on the clinical role of ex vivo lung perfusion (EVLP) with acellular perfusate. | J Thorac Dis | 2025 | 41522104 | PubTator, text mining | PubMed |
| Bladder Neck Incision in Posterior Urethral Valve Management: a Meta-Analysis with Insights into Adjunctive Bladder Interventions. | Curr Urol Rep | 2025 | 41432817 | PubTator, text mining | PubMed |
| CD155 reprograms glycolysis via the YAP/TEAD1-GLUT1 axis to promote lung adenocarcinoma progression and M2 macrophage polarization: a metabolic-immune target visualized by 18F-FDG PET/CT. | J Transl Med | 2025 | 41430237 | PubTator, text mining | PubMed |
| Proteomic profiling of Alzheimer's disease and Vascular dementia reveals unique underlying signatures. | medRxiv | 2025 | 41415504 | PubTator, text mining | PubMed |
| CD155-based chimeric antigen receptor T cells: a promising immunotherapy for cervical and breast cancer. | Front Immunol | 2025 | 41394877 | PubTator, text mining | PubMed |
| Post-radiation targeting of TIGIT and CD96 improved immunotherapy efficacy in head and neck squamous cell carcinoma. | Mol Med | 2025 | 41382272 | PubTator, text mining | PubMed |
| Expression of Poliovirus Receptor, the Ligand of TIGIT, Associated With Immune-Cold Tumor Microenvironment in Hepatocellular Carcinoma. | JCO Precis Oncol | 2025 | 41370729 | PubTator, text mining | PubMed |
| Arecoline upregulates CD155 expression to facilitate immune evasion in oral squamous cell carcinoma. | J Immunother Cancer | 2025 | 41365532 | PubTator, text mining | PubMed |
| Tumor targeting dendritic nanocarrier with immunogenic cell death inducing and TIGIT blockade for synergistic chemo-immunotherapy against TNBC. | J Nanobiotechnology | 2025 | 41354959 | PubTator, text mining | PubMed |
| Immunotherapeutic strategies targeting the PVR-TIGIT/CD96/CD226 signaling pathway in glioma treatment. | Ann Med | 2025 | 41254994 | PubTator, text mining | PubMed |
| Clinical significance of CD155 expression and correlation with immune cell infiltration in triple-negative breast cancer. | Transl Cancer Res | 2025 | 41234834 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5817/papers?page=10